1 Elevated blood glucose levels are associated with the progression of brain hypometabolism, and HDL-C 2 and APOE4 add to this association Aravind Lathika Rajendrakumar<sup>1</sup>, Svetlana Ukraintseva<sup>1</sup>, Olivia Bagley<sup>1</sup>, Matt Duan<sup>1</sup>, Anatoliy I. Yashin<sup>1</sup>, 3 Konstantin G. Arbeev<sup>1\$\$</sup>; for the Alzheimer's Disease Neuroimaging Initiative<sup>§</sup> 4 5 6 **Abstract** 7 **Background:** Brain glucose hypometabolism has consistently been found in neurodegenerative disorders, 8 including Alzheimer's disease (AD). High blood glucose and HDL cholesterol (HDL-C) levels have also been 9 linked to neurodegeneration and AD. However, there is limited understanding of the relationships 10 between dementia-related risk factors in the brain and blood. 11 Methods: A linear mixed model was used to examine the relationship between blood glucose and HDL-C 12 levels and the progression of brain hypometabolism, adjusting for APOE4 and other clinical covariates. 13 The hypometabolic convergence index (HCI) was measured by fluorodeoxyglucose-18 (FDG) positron 14 emission tomography (PET) in participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI). 15 Data visualizations were generated to understand the joint effects of plasma glucose, HDL-C, and APOE4 16 on HCI. 17 Results: There were 336 individuals (781 observations), of whom 22.62% had AD. The majority were male 18 (63.98%) and of white race, and 48.51% were carriers of APOE4. Over time, high blood glucose level was 19 associated with the progression of brain glucose hypometabolism (β=0.33, 95% CI: 0.02, 0.64, p<0.05). A 20 high plasma HDL-C level ( $\beta$ =1.22, 95% CI: 0.09, 2.35, p<0.05), more study visits ( $\beta$ =1.67, 95% CI: 1.37, 1.98, p<0.001), and being an APOE4 allele carrier ( $\beta$ =1.29, 95% CI: 0.15, 2.42, p<0.05) were also significant 21

predictors of brain hypometabolism progression. APOE4 carrier status and number of visits account for

the largest proportion of the variance from the fixed effects model. Random effects due to participant

22

characteristics and fixed effects together accounted for 95.2% of the model variance. Subgroup analysis

revealed that these effects were observed only in those without AD.

### **Conclusion:**

High plasma glucose levels facilitated the progression of brain hypometabolism. The effect was more prominent in the *APOE4* double-carriers with elevated HDL-C. Elevated blood glucose may reflect systemic insulin resistance, which could impair brain glucose uptake, resulting in brain hypometabolism.

Controlling blood glucose and HDL-C levels in APOE4 carriers may improve brain metabolism, potentially

delaying the onset of dementia.

# Keywords

Brain hypometabolism, Blood glucose, HDL cholesterol, APOE4, Alzheimer's disease, Hypometabolic

Convergence Index

### **Background**

Glucose usage in the brain has been finely tuned throughout evolution.<sup>1</sup> Brain cells are highly energy-dependent and require a constant supply of glucose for optimal functioning.<sup>2</sup> Glucose meets the energy demands for a diverse range of activities, including brain signaling, neurotransmitter production, and maintaining homeostasis.<sup>3</sup> Due to this, multilayered mechanisms, including sensors, glucose transporters, enzymes, and specific cell pathways, work together to ensure the availability of glucose.<sup>2</sup> Complex learning processes in neurons and astrocytes are correlated with brain metabolism, which is directly dependent on glucose usage.<sup>4</sup> Exposure to insufficient glucose supply can harm memory and learning, and prolonged insufficiency can potentially cause permanent brain alterations.<sup>3</sup> Thus, any deviation from the normal glucose uptake pattern in the brain might indicate a serious medical illness.<sup>5</sup>

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

Earlier neuroimaging studies have considerably expanded our knowledge of metabolic alterations in dementia.<sup>6,7</sup> Neuroimaging outcomes are superior to traditional cognitive assessments in detecting related changes and correlate well with neuropathological changes in individuals with dementia.8 A pattern of glucose deficit in the brain is noted for several neurodegenerative disorders, which can be distinguished among the relevant conditions. In the case of Alzheimer's disease (AD), hypometabolism begins much earlier than the actual onset of clinical symptoms and contributes to the further progression of the disease. 10 The [18F]-2-fluoro-2-deoxy-2-glucose (FDG) tracer-based positron emission tomography (PET) is a widely used diagnostic method to ascertain the metabolic rate in different tissues. FDG mimics glucose absorption and remains in the body longer than glucose. Studying its buildup in tissues helps quantify the metabolic rate. 11 The FDG PET-derived hypometabolic convergence index can accurately distinguish the AD signature brain hypometabolic pattern through automated brain image analysis. Dementia subtypes, such as AD, have a complex, multifactorial etiology, stemming from an interplay between aging, genetics, and the environment. <sup>12</sup> In this context, among the risk factors, hyperglycemia, and particularly diabetes, are major concerns due to its rising global prevalence. 13 Clinical features of diabetes, such as abnormal insulin signaling and insulin resistance, are also pathological features of dementia.14 Lipids are another risk factor that deserves attention in the control of dementia.15 Until recently, it was believed that elevated levels of HDL cholesterol were beneficial for health. <sup>16</sup> Indeed, numerous studies demonstrated protective associations between elevated HDL cholesterol levels and reduced risk of heart disease, inflammatory conditions, and even cognitive decline.<sup>17</sup> The protective effects of HDL may be attributed to its antioxidant and anti-inflammatory properties, as well as its ability to remove excess 'bad' cholesterol. 18 Based on several such studies, it has even suggested that increasing HDL levels or restoring its functions could be explored as a therapeutic option to combat inflammation and AD. 19,20

Emerging evidence, however, has now challenged this established understanding.<sup>21</sup> Despite these findings, there is a lack of evidence regarding the connections between dementia risk factors in the brain and in the blood. The combination of risk factors might drive individual differences in dementia progression.<sup>10</sup> Therefore, examining the combination of hypometabolism risk factors, such as blood glucose and HDL-C levels, may provide more insights into individual differences in dementia progression.

The presence of the *APOE4* allele significantly increases the risk of developing AD.<sup>22</sup> Despite numerous research studies, many aspects of the role of *APOE4* in AD remain unclear, including its interaction with dementia risk factors.<sup>23</sup> Due to these reasons, we also sought to explore how the effects were modified when these risk factors were present in carriers of *APOE4*.

### Methods:

### Data Source

We conducted this analysis using the Alzheimer's Disease Neuroimaging Initiative (ADNI) database. The ADNI project was started in 2004 with Michael Weiner as the chief investigator. This project is a part of public-private collaboration that includes major institutions across North America. ADNI encourages the cost-free sharing of deep genotyped and phenotyped datasets with interested researchers worldwide. ADNI collects biomarkers, brain scans, clinical data, and cognitive assessments from volunteer participants based on a preset inclusion criteria. ADNI seeks to improve clinical prediction of AD and its treatment by leveraging the wide variety of available longitudinal neuroimages, biomarkers, and cognitive scales.

## **Details of FDG PET Imaging**

FDG PET imaging was performed on a subset of participants based on a standard protocol. Data gathered within ADNI are allocated to different cores, each comprising experts specializing in corresponding

domains, tasked with efficiently managing the data.<sup>24</sup> There are two imaging cores, with PET imaging falling under the jurisdiction of Banner Institute, which specifies parameters to maintain optimal imaging quality. To ensure comparability and quality across various scanners, a 3D correction is applied to the acquired images. For more information on PET measurements in the ADNI study, refer to Mueller et al.'s publication.<sup>8</sup>

# **Generation and Interpretation of Hypometabolic Convergence Index Scores**

We investigated the longitudinal changes in hypometabolic convergence index (HCI) as the study outcome. HCI values were accessed from the BAIPETNMRCFDG dataset (<a href="https://adni.bitbucket.io/reference/baipetnmrc.html">https://adni.bitbucket.io/reference/baipetnmrc.html</a>). The HCI was generated from comprehensive whole-brain image analysis rather than regional examination of FDG PET brain images, and summarizes the extent of brain hypometabolism in the form of z-scores. These scores were obtained through voxel-wise analysis of the images using Statistical Parametric Mapping (SPM) software. An increasing HCI was interpreted as indicative of greater brain hypometabolism.

# Covariate Extraction, Measurements, and Data linkage

We extracted glucose and lipid biomarkers from the ADNINIGHTINGALELONG dataset. In ADNI, *APOE4* was measured using DNA extracted by Cogenics from a 3 mL aliquot of EDTA blood collected during participant screening visits.<sup>27</sup> Only rows containing values for all the variables were further considered for the analysis. Information on smoking and alcohol use was obtained from the medical history file. Data regarding systolic and diastolic blood pressure, sex, marital status, race, and education were derived from the vitals and demographics datasets. Age was calculated as the difference in years between the

examination date and the date of birth for each participant over time. Diabetes medications were extracted from the medication data using the Anatomical Therapeutic Classification (ATC) codes (<a href="https://www.who.int/tools/atc-ddd-toolkit/atc-classification">https://www.who.int/tools/atc-ddd-toolkit/atc-classification</a>). When applicable, we used the visit code and distinct participant identifier to link datasets. Once linked, a participant was considered to be taking diabetes medication for all subsequent data following the initial prescription. We utilized the tidyr package's *fill* function with the 'direction=down' option to propagate the diabetes medication use labels.

## **Statistical Analysis**

We performed data analysis and visualizations using the R programming language (R version 4.3.2). <sup>28</sup> At first, variable summaries measured at baseline were computed. For this, continuous variables were presented as mean with standard deviation. Categorical variables were summarized as frequencies and percentages. To depict correlations between continuous covariates at the baseline, we employed a correlation heatmap. To assess longitudinal variations in plasma glucose and HDL-C levels, we pooled all observations from all visits and calculated the coefficient of variation percentage (CV%). CV% was computed by dividing the standard deviation by the mean and multiplying by 100. We generated a scatter plot of the CV% for glucose and HDL-C distributions to assess their relationship. Additionally, we plotted the CV% for these measures stratified by *APOE4* allele status and determined if the differences were statistically significant using the Kruskal-Wallis test.

To examine the relationship between blood glucose, HDL-C levels, *APOE4* status, and the progression of brain hypometabolism, and to account for the correlated data structure, we conducted a linear mixed model analysis using the lme4 package.<sup>29</sup> Variations between participants and visits were accounted for by specifying random intercepts and varying slopes in the random effects part of the model. We analysed

multiple models with different combinations of terms and then selected the best model with the lowest Akaike Information Criterion (AIC) values. This model was deemed the model with the minimum set of variables that best explains the data. Model comparisons were performed using the anova built-in function. For unbiased regression estimates in the optimal model, we employed restricted maximum likelihood estimation. The Nelder-Mead optimizer was used to ensure model convergence.

To analyze the conditional and marginal variable contributions of the covariates in the parsimonious mixed model, we utilized the hierarchical partitioning method.<sup>30</sup> This approach helps to understand how *APOE4*, HDL-C, and glucose modify the HCI. We computed marginal means and corresponding 95% confidence intervals (CI) to quantify the average change in HCI for these variables.

We also checked the functional relationship between glucose and HDL-C with HCI using generalized additive mixed effect models (GAMM). The advantage of GAMM is that it is able to incorporate the benefits of generalized additive models, i.e., nonlinear effects modeling, while also accounting for correlations due to repeated measures.<sup>31</sup> The AIC from both linear and nonlinear models were compared to determine the most suitable functional relationship between the variables. A two-tailed p-value <0.05 was considered statistically significant. Additionally, we quantified and visualized individual heterogeneity for the random effects terms specified in the optimal mixed effects model. Lastly, to assess the HCI reduction associated with varying values of glucose and HDL-C, we generated a partial effect plot.

## Results

#### Sample description

Data on 336 individuals (781 observations) were available for analysis after data linkage, with 22.62% of participants diagnosed with AD (Supplementary Figure 1). Table 1 describes the baseline demographic and clinical characteristics of the participants in this study. The participants were, on average, 75.43 years

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175


old and had 15.6 years of education. The majority were male (63.98%) and White (93.45%). Over a third (38%) had a smoking history, and 97.6% reported being ever married. The mean HbA1C and HDL-C levels were 5.42 and 1.52, respectively. The mean systolic blood pressure (SBP) was relatively high at 135 mm Hg, whereas the mean diastolic blood pressure (DBP) was below the normal reference level at 73.77 mm Hg. Almost half (48.51%) were carriers of the APOE4 allele. Figure 1 shows the distribution of longitudinal CV% for glucose and HDL-C, as well as their relationship. In Figure 2, the distributions of longitudinal CV% for glucose and HDL-C, stratified by APOE4 allele status, are shown. Non-linear modeling (spline fit) of the relationship between CV% for glucose and HDL-C supports a nonlinear relationship. P-values from the Kruskal-Wallis test to see the influence of APOE4 alleles on the CV% for glucose and HDL-C were nonsignificant (0.78 and 0.56, respectively). Brain hypometabolism, measured by HCI, was higher in this sample, with a mean of 15.06 (range 4.34 - 47.40). Initially, only 2 participants (0.60%) were using antidiabetes medication, but by the end of the follow-up, this number had risen to 10 (2.97%). As regards to the baseline correlations, APOE4 was positively correlated to HCI (Supplementary Figure 2). APOE4 had no strong correlations with either lipid subgroups and blood glucose. In those with AD, blood glucose and HDL-C modelled using splines seems to favor a more non-linear relationship in comparison to those not diagnosed with AD (Supplementary Figures 3-4).

Table 1. Characteristics of participants measured at baseline (781 observations, n=336)

Variables	Mean (Frequency)	SD	Range
Age (Years)	75.43	6.69	55.24 -89.00
Sex (Male)	215 (63.98%)		
Education (Years)	15.66	2.96	6-20

Blood Glucose (mmol/L)	5.42	0.87	2.99-10.47
HDL-C (mmol/L)	1.52	0.39	0.73 – 3.29
Race (White)	314 (93.45%)		
Married (Ever)	328 (97.61%)		
Smoking (Ever)	126 (37.50%)		
Alcohol (Ever)	11 (3.27%)		
AD	76 (22.61%)		
APOE4			
0	173 (51.48%)		
1	131 (38.98%)		
2	32 (9.52%)		
SBP (n=335)	135.12	16.59	90-201
DBP (n=335)	73.77	9.23	43-98
NonHDL-C	3.49	1.60	1.21-6.16
LDL-C	2.01	0.46	0.61 – 3.47
HCI	15.06	7.54	4.34 - 47.40

Note. SBP = Systolic Blood Pressure; DBP = Diastolic Blood Pressure; NonHDL-C = Non-High-density lipoprotein cholesterol; LDL-C = Low-density lipoprotein cholesterol; HDL-C = High-density lipoprotein cholesterol; HCI = Hypometabolic Convergence Index.



**Figure 1**. Histogram of longitudinal CV% for glucose and HDL-C, and a scatterplot with smoothed regression line showing their relationship




Figure 2. Distribution of longitudinal CV% for glucose and HDL-C stratified by APOE4 allele status

# Effect of Elevated Blood Glucose and HDL-C Variability on Brain Hypometabolism

As shown in the Supplementary Table 1, Model 2 was selected for detailed analysis. Table 2 shows the adjusted regression estimates from the optimal linear mixed model. More number of clinical visits ( $\beta$ =1.67, 95% CI: 1.37, 1.98, p<0.001), and *APOE4* carrier status were the strongest predictors for the decline in brain metabolism in ascending order respectively (Supplementary Figure 5). The contributions of these variables to variance from fixed effects in the best model were also the highest. Over time, an increase in plasma glucose was significantly associated with an increased area of brain hypometabolism ( $\beta$ =0.33, p<0.05). None of the cholesterol markers except HDL-C were statistically significant in the multivariate analysis ( $\beta$ =1.22, p<0.05). Additionally, age, sex, smoking, blood pressure, and race were not significant predictors. The percentage variance of the fixed effects (marginal R-squared) was estimated at 4.5%. Supplementary Figure 6 elucidates the random effects represented by the clinical visits and individual variability. Variance, combining both the fixed and random effects (conditional R-squared), accounted for 95.2% of the model variance.

**Table 2**. Adjusted model estimates corresponding to the optimal linear mixed model for the HCI trend outcome

Variable	Coefficient	95% CI	p-value
Glucose	0.33	0.02, 0.64	0.034*
HDL-C	1.22	0.09, 2.35	0.032*
APOE4	1.29	0.15,2.42	0.023*
Race (White)	2.85	-0.09,5.79	0.060
Visits	1.67	1.37,1.98	0.000***

Note. \*p<0.05; \*\*\*p<0.001

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224


225

Functional Relationship Between Glycemic Variability, HDL-C Levels, and Their Interaction with *APOE4* on Brain Hypometabolism


A comparison of effects plots (Supplementary Figure 7, Figure 3, and Figure 4) generated from linear and

additive mixed models (GAMM) indicates that glucose has a linear relationship with HCI. Conversely, HDL-C showed a nonlinear relationship, which was preferred over the linear model. Additive mixed models work similarly to linear mixed models, with the difference being that they allow for modeling complex non-linear relationships of variables by fitting smooth functions.<sup>31</sup> Partial effects here refer to the mean effect in HCI due to the change in exposures while keeping the effects of other covariates held constant in the model. The dose-response relationship between HDL-C and HCI was observed to decrease slightly, stabilize and then decline after 2 mmol/L for higher values. According to Figure 4, elevated HDL-C reduces brain metabolism even when glucose levels are optimal. Hypometabolism increases with each unit rise in glucose, particularly above 7.5 mmol/L. At this threshold, risk is evident even for low HDL-C values. Hence, it could be deduced that elevated glucose values are an important risk factor for brain hypometabolism, and that its effects with HDL-C on brain metabolism are non-linear. Supplementary Figure 8 complements this finding, showing substantial differences in predicted HCI across stratified HDL-C categories of low, intermediate, and high levels. Similar trends were evident in the interaction effects of blood glucose levels, HDL-C, and the APOE4 allele on HCI (Figure 5). The plot shows a dramatically pronounced decline in brain metabolism for increased blood glucose levels and HDL-C in APOE4 homozygous carriers compared to non-carriers and heterozygous carriers. In addition, for better interpretation of the slopes, the marginal means for the HCI, computed for the different combinations of these risk factors, are shown in Supplementary Table 2.


Compared to non-carriers with low HDL-C and high glucose, there was a more than 10-point increase in predicted mean HCl for double *APOE4* carriers with high HDL-C.



**Figure 3.** Partial effects of Glucose and HDL-C levels on the HCI from the GAMM model. Note. TPRS (thin plate regression splines) are basis functions that allow for model fitting of local segments of the exposure-outcome relationship, which are then connected to provide a complete picture of the overall relationship. Thin plate splines automatically determine the location and number of knots based on changes in the values of the covariate.



**Figure 4.** The partial effect plot illustrates the combined effects of HDL-C and glucose levels on HCI. The variable relationships are shown as a smoothed relationship as a function of these variables and are estimated from the additive mixed model. In the plot, the black lines and black dots represent the contour lines and observed data points, respectively. A change in color from green to orange reflects how the relationship changes, i.e., from a negative to a positive partial effect. A partial effect of -1 means that a one-unit increase in the predictor variable is associated with a one-unit decrease in the outcome variable, and vice versa. It is evident that the partial effects vary at different levels of the predictor variables.



**Figure 5**. Plot showing the synergistic effects of blood glucose levels, HDL-C, and *APOE4* allele on HCI. The predictions were generated from a model containing interaction terms for blood glucose levels, HDL-C, and *APOE4*. Each window corresponds to the effects of the *APOE4* allele (0, 1, 2) and is shown specifically for HDL-C categories (low, high, and intermediate, arbitrarily selected based on the data)

## **Comparison of Subgroup Analysis to Identify Heterogeneity in Effects**

Given that the visualizations indicated a possible difference in the effects of the exposures in AD and non-AD individuals, we prepared the data accordingly. Upon further investigation, we noted that the statistical associations were limited to the non-AD subgroup (Supplementary Tables 3-4). Remarkably, the strength of the associations for White race, HDL-C, and *APOE4* with HCl was much stronger in the stratified analysis for this group. Overall, the effect size for glucose did not differ for the non-AD individuals compared to the main analysis, whereas the clinical visits exhibited a diluted effect. For the AD group, both *APOE4* and visits were still significantly associated with HCl. While the impact of visits was considerably stronger than in the aggregated model, the effects of *APOE4* were strongly reversed, indicating a protective association.

## Discussion

In this study of older adults, plasma glucose and HDL-C variability were significantly associated with a reduction in brain metabolism, but only in individuals without AD. Importantly, these effects were independent of *APOE4* and common confounders such as age, sex, and other lipids profiles. We also found that the relationship of plasma glucose and HDL-C with brain metabolism operates independently of each other. *APOE4* status and measurement visit were the strongest predictors of brain metabolism at the population level. This is not surprising, as we demonstrated in our previous work using the ADNI data that measurement visits provide more information than age alone.<sup>32</sup> Measurement visits may indirectly reflect patient characteristics, response, and observation time.<sup>33</sup>

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

A hyperglycemic milieu can cause widespread systemic effects, thereby modulating physiological responses.<sup>34</sup> It is important to note that the diabetes burden was quite low in our data. However, diabetes is not an absolute requirement for the glucose to impact brain. Our findings are consistent with a previous study which demonstrated that even midlife increase in glucose can accelerate dementia.<sup>35</sup> Although hyperglycemia contributes to the development of dementia, its role in certain types of dementia such as in AD remains to be established.<sup>36</sup> In our case, one possible reason could be that participants had AD at baseline and, therefore, already had much lower brain metabolism. Therefore, it is much less likely that glucose and HDL-C variations would have any impact. Also, APOE4 is no more a risk factor since they had already developed AD. Hyperglycemia-induced physiological changes are quite complex and usually do not conform to the normal dose-response framework.<sup>37</sup> However, in our study, an increase in blood glucose levels was linearly related to a decline in brain metabolism. This contradicted a previous study in which cognitive decline was observed with both high and low blood sugar levels, and it worsened with age.<sup>38</sup> Nevertheless, high blood sugar-driven outcomes at the individual level are highly heterogeneous and also depend on the combination of other risk factors and genes. 39,40 In our data, elevated HDL-C was stronger risk factor for brain hypometabolism than plasma glucose levels. The role of lipids in dementia remains controversial. A meta-analysis of multiple studies published on lipid subgroups shows that LDL-C could be a likely candidate risk factor for dementia, but there was no evidence of involvement of HDL-C or other lipids. <sup>41</sup> On the other hand, it is worth noting that high HDL-C levels could negatively impact health and survival, including increased all-cause and cardiac-related mortality. However, individuals in the mid-range levels of HDL-C seem to be protected.<sup>42</sup> This was observed in the 'U-shaped' relationship between HDL-C levels and cognitive outcomes, with individuals having HDL-C values above 2.50 mmol/L experiencing more than a two-fold increased risk of poor cognitive outcomes.<sup>43</sup> Such a relationship was also reported in a large-scale survival analysis of health insurance data exploring

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

dementia outcome. Similar to our study, LDL-C in this study did not influence dementia risk, except for a minor increase in risk observed among statin users.<sup>44</sup> A study published in Lancet, that investigated whether HDL-C is a risk factor for incident dementia reported a risk above 3.3 mmol/L. <sup>45</sup> Consistent with the previous findings, individuals aged above 75 years with high HDL-C were at substantial risk for dementia. In stark contrast, lower HDL-C values were shown to be protective against dementia.<sup>45</sup> This was in line with our finding. Based on the partial effects plots in our study, HDL-C associated risk appeared to diminish beyond 2.25 mmol/L. However, these findings require further validation, as there were only a few HDL-C values above this threshold in the data. It might be that the HDL-C effects seen were due to the presence of AD, co-morbidities, or other age-related factors. In such scenarios, high HDL would be merely reflective of these conditions rather than providing any real health benefits.20 APOE4 carriage was associated with a greater metabolic decline compared to non-carriers for the concomitant values of glucose and HDL-C. Notably, this interaction was particularly strong in individuals with HDL-C levels above 2 mmol/L. It is intriguing that the direction of the predicted slope for brain hypometabolism with glucose elevation was similar at lower HDL values across all APOE4 isoforms, with carriers experiencing a slightly higher metabolic decline. The observed interaction effects appear plausible as APOE4 have a direct link with cholesterol metabolism and lower HDL synthesis. 46-48 In addition it has been observed that mice with APOE4 risk alleles exhibit a poor response to glucose spikes and inadequate insulin production.<sup>49</sup> Individuals with APOE4 risk alleles and high blood glucose were more likely to experience greater risk for severe dementia and features of AD in late life.35 First of all, carrying two APOE4 alleles is now considered a genetic form of AD by itself.<sup>50</sup> Our finding regarding the synergistic effect modulated by APOE4 double carriers is in firm agreement, showing a vastly different pattern of hypometabolism compared to its other isoforms. Therefore, the effects in those without AD might actually be congruent with preclinical AD.<sup>51</sup> This should be kept in mind, especially in the context that the

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

diagnostic criteria for AD are still evolving.<sup>51</sup> APOE4 carrier status favors AD and dementia mainly through promoting amyloid beta, increased phosphorylated tau, and contributing to neurodegeneration. <sup>27,52,53</sup> It is also recognized that APOE4 variation can negatively impact mitochondrial respiration and energy production, consequently leading to brain hypometabolism.<sup>54</sup> Other potential pathways include neuroinflammation, blood-brain barrier dysfunction, gliosis, brain structural and functional changes, demyelination and impaired clearance of toxic substances. 55-60 In relevance to our work, it has already been demonstrated that APOE4 variation adversely impacts the ability of HDL-C to effectively sequester cholesterol by modifying HDL-C structurally. Not only does the concentration of HDL matter, but also its size. For instance, individuals with AD and dementia tend to have relatively smaller HDL particle sizes. 61 We presume that APOE4-induced changes in the brain may make it more vulnerable to the negative physiological effects of elevated glucose and other risk factors. As corroborating evidence, we found no indication that longitudinal variability in glucose and HDL-C can be attributed to APOE4 alleles. This study has several strengths including the availability of serial participant data and a well-characterized cohort. Our study is among the first to illuminate the joint contributions of glucose, HDL-C, and APOE4 allele variations on brain hypometabolism. We were able to clearly demonstrate the change in relative importance of these major risk factors through visualizations. This approach provides a more comprehensive understanding of the potential pathophysiology, which may not be fully revealed when examining these factors individually. Our study had limitations. Blood glucose and HDL-C collection was not timed according to disease pathology. The study did not account for comorbidity status or medication use as covariates, with the exception of blood pressure, and diabetes. We have not specifically investigated the possibility of sexual dimorphism in our results, nor have we considered the involvement of potential mechanisms such as

amyloid pathways or other inflammatory markers. Another constraint was the limited representation of non-white samples, which restricted our ability to compare and explore differences across racial groups. This, combined with the smaller sample size and selective recruitment in the cohort, may further limit the generalizability of the findings. Lastly, there could be unmeasured confounding. Therefore, we recommend replicating our findings in large cohorts and across multiple ethnicities to ascertain the benefits of glucose and HDL reduction in diverse populations. Further studies may be conducted using genetic variants that influence these exposures to gather causal evidence.

### Conclusion

High blood glucose levels facilitated progression of cerebral hypometabolism in ADNI participants. The negative impact of blood glucose on brain hypometabolism was aggravated by elevated HDL-C levels and APOE4 carrying status. High blood glucose levels may reflect systemic insulin resistance, which, in turn, might impair brain glucose uptake, resulting in brain hypometabolism. While further validation is warranted, controlling for plasma glucose/insulin resistance and HDL-C levels in APOE4 carriers may attenuate the decline in brain metabolism, potentially delaying dementia clinical onset.

#### **Abbreviations**

ΑD

ADNI	Alzheimer's Disease Neuroimaging Initiative
ATC	Anatomical Therapeutic Classification
CV%	Coefficient of Variation Percentage
DBP	Diastolic Blood Pressure (DBP)

Alzheimer's Disease

FDG Fluorodeoxyglucose-18 (FDG) Generalized Additive Mixed Effect Models **GAMM** HCI Hypometabolic Convergence Index HDL-C High-density lipoprotein cholesterol LDL-C Low-density lipoprotein cholesterol NonHDL-C Non-High-density lipoprotein cholesterol PET **Positron Emission Tomography SBP** Systolic Blood Pressure (SBP) SPM Statistical Parametric Mapping **TPRS** Thin Plate Regression Splines References Harris JJ, Jolivet R, Attwell D. Synaptic Energy Use and Supply. Neuron. 2012;75(5):762–77. 1. 2. Mergenthaler P, Lindauer U, Dienel GA, Meisel A. Sugar for the brain: The role of glucose in physiological and pathological brain function. Vol. 36, Trends Neurosci. 2013. 587–97. 3. Hertz L, Gibbs ME. What learning in day-old chickens can teach a neurochemist: focus on astrocyte metabolism. J Neurochem. 2009;109(Suppl 1):10-6.

356

357

358

359

360


361

362


363

364

365



388 389 11. Pauwels EKJ, Coumou AW, Kostkiewicz M, Kairemo K. [18F] Fluoro-2-deoxy-D-glucose positron 390 emission tomography/computed tomography imaging in oncology: Initial staging and evaluation of cancer therapy. Med Princ Pract. 2013;22(5):427-37. 391 392 Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. The Lancet. 2006;368(9533):387–403. 393 12. 394 395 13. Sims-Robinson C, Kim B, Rosko A, Feldman EL. How does diabetes accelerate Alzheimer disease 396 pathology? Nat Rev Neurol. 2010;6(10):551-9. 397 398 Nguyen TT, Ta QTH, Nguyen TKO, Nguyen TTD, Giau V Van. Type 3 Diabetes and Its Role 14. Implications in Alzheimer's Disease. Int J Mol Sci. 2020;21(9):3165. 399 400 401 15. Zhu Y, Liu X, Zhu R, Zhao J, Wang Q. Lipid levels and the risk of dementia: A dose-response meta-402 analysis of prospective cohort studies. Ann Clin Transl Neurol. 2022;9(3):311. 403 Rajagopal G, Suresh V, Sachan A. High-density lipoprotein cholesterol: How High. Indian J 404 16. 405 Endocrinol Metab. 2012;16(2). 406



427 23. Mosconi L, Herholz K, Prohovnik I, Nacmias B, Cristofaro MTR De, Fayyaz M, et al. Metabolic 428 interaction between ApoE genotype and onset age in Alzheimer's disease: implications for brain 429 reserve. J Neurol Neurosurg Psychiatry. 2005;76:15-23. 430 431 24. Jack CR, Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D, et al. The Alzheimer's Disease 432 Neuroimaging Initiative (ADNI): MRI Methods. J Magn Reson Imaging. 2008;27(4):691. 433 Chen K, Ayutyanont N, Langbaum JBS, Fleisher AS, Reschke C, Lee W, et al. Characterizing 434 25. 435 Alzheimer's disease using a hypometabolic convergence index. Neuroimage. 2011;56:52–60. 436 437 26. Caroli A, Prestia A, Chen K, Ayutyanont N, Landau SM, Madison CM, et al. Summary Metrics to 438 Assess Alzheimer Disease-Related Hypometabolic Pattern with 18F-FDG PET: Head-to-Head 439 Comparison. J Nucl Med. 2012;53(4):592-600. 440 441 Sudre CH, Cardoso MJ, Frost C, Barnes J, Barkhof F, Fox N, et al. APOE £4 status is associated with 27. 442 white matter hyperintensities volume accumulation rate independent of AD diagnosis. Neurobiol Aging. 2017;53:67-75. 443 444 445 28. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2021. 446 447

448 29. Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models Using Ime4. J Stat 449 Softw [Internet]. 2015:67(1):1-48. 450 451 30. Lai J, Zou Y, Zhang S, Zhang X, Mao L, Zhang WH. glmm.hp: an R package for computing individual 452 effect of predictors in generalized linear mixed models. Journal of Plant Ecology [Internet]. 2022 453 Dec 1 [cited 2023 Jul 2];15(6):1302-7. 454 455 R package version 0.2-6. gamm4: Generalized Additive Mixed Models using "mgcv" and "lme4" 31. [Internet]. 2020 [cited 2024 Jul 16]. Available from: https://CRAN.R-project.org/package=gamm4. 456 457 458 32. Rajendrakumar AL, Arbeev KG, Bagley O, Yashin AI, Ukraintseva S, Initiative for the ADN. The SNP 459 rs6859 in NECTIN2 gene is associated with underlying heterogeneous trajectories of cognitive 460 changes in older adults. BMC Neurol. 2024;24(78). 461 462 Coulombe J, Moodie EEM, Shortreed SM, Renoux C. Estimating individualized treatment rules in 33. longitudinal studies with covariate-driven observation times. Stat Methods Med Res. 463 464 2023;32(5):868-84. 465 466 34. Mcmurry HS, Mendenhall E, Rajendrakumar A, Nambiar L, Satyanarayana S, Shivashankar R. Coprevalence of type 2 diabetes mellitus and tuberculosis in low - income and middle - income 467 countries: A systematic review. Diabetes Metab Res Rev. 2019;35(2018). 468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

35. Bangen KJ, Himali JJ, Beiser AS, Nation DA, Libon DJ, Fox CS, et al. Interaction between midlife blood glucose and APOE genotype predicts later Alzheimer pathology. J Alzheimers Dis. 2016;53(4):1553-62. 36. Doney ASF, Bonney W, Jefferson E, Walesby KE, Bittern R, Trucco E, et al. Investigating the Relationship Between Type 2 Diabetes and Dementia Using Electronic Medical Records in the GoDARTS Bioresource. Diabetes Care. 2019;42(10):1973-80. Rajendrakumar AL, Hapca SM, Nair ATN, Huang Y, Chourasia MK, Kwan RSY, et al. Competing risks 37. analysis for neutrophil to lymphocyte ratio as a predictor of diabetic retinopathy incidence in the Scottish population. BMC Med. 2023;21(1):304. 38. Chakrabarty R, Yousuf S, Singh MP. Contributive Role of Hyperglycemia and Hypoglycemia Towards the Development of Alzheimer's Disease. Mol Neurobiol. 2022;59(7):4274-91. 39. Nair ATN, Wesolowska-Andersen A, Brorsson C, Rajendrakumar AL, Hapca S, Gan S, et al. Heterogeneity in phenotype, disease progression and drug response in type 2 diabetes. Nat Med. 2022;28:982-8.

489 40. Lathika Rajendrakumar A, Narayanan Nair AT, Chourasia MK, Nangia C, Srinivasan S, Radha V, et 490 al. Multi-ancestry genome-wide association study of neutrophil-lymphocyte ratio and polygenic 491 risk score development to explore causal association with diabetic retinopathy, medRxiv. 2024 Jan 492 1;2024.06.19.24309194. 493 494 41. Sáiz-Vazquez O, Puente-Martínez A, Ubillos-Landa S, Pacheco-Bonrostro J, Santabárbara J. Cholesterol and Alzheimer's Disease Risk: A Meta-Meta-Analysis. Brain Sci. 2020;10(6):386. 495 496 Liu C, Dhindsa D, Almuwaggat Z, Ko YA, Mehta A, Alkhoder AA, et al. Association Between High-497 42. 498 Density Lipoprotein Cholesterol Levels and Adverse Cardiovascular Outcomes in High-risk 499 Populations. JAMA Cardiol. 2022 Jul 1;7(7):672–80. 500 501 43. Huang H, Yang B, Yu R, Ouyang W, Tong J, Le Y. Very high high-density lipoprotein cholesterol may 502 be associated with higher risk of cognitive impairment in older adults. Nutr J. 2024;23(79). 503 Ferguson EL, Zimmerman SC, Jiang C, Choi M, Swinnerton K, Choudhary V, et al. Low- and High-504 44. Density Lipoprotein Cholesterol and Dementia Risk Over 17 Years of Follow-up Among Members 505 506 of a Large Health Care Plan. Neurology. 2023;101(21):e2172-84. 507

508 45. Monira Hussain S, Robb C, Tonkin AM, Lacaze P, T-J Chong T, Beilin LJ, et al. Association of plasma 509 high-density lipoprotein cholesterol level with risk of incident dementia: a cohort study of healthy 510 older adults. Lancet Reg Health West Pac. 2023;43(100963). 511 512 46. Dunk MM, Li J, Liu S, Casanova R, Chen JC, Espeland MA, et al. Associations of dietary cholesterol 513 and fat, blood lipids, and risk for dementia in older women vary by APOE genotype. Alzheimer's Dement. 2023;19:5742-54. 514 515 Garcia AR, Finch C, Gatz M, Kraft T, Eid Rodriguez D, Cummings D, et al. APOE4 is associated with 516 47. 517 elevated blood lipids and lower levels of innate immune biomarkers in a tropical Amerindian subsistence population. Goldberg A, Perry GH, editors. Elife. 2021;10:e68231. 518 519 520 48. Hopkins PCR, Huang Y, McGuire JG, Pitas RE. Evidence for differential effects of apoE3 and apoE4 521 on HDL metabolism. J Lipid Res. 2002;43(11):1881-9. 522 Koren-Iton A, Salomon-Zimri S, Smolar A, Shavit-Stein E, Dori A, Chapman J, et al. Central and 523 49. Peripheral Mechanisms in ApoE4-Driven Diabetic Pathology. Int J Mol Sci. 2020;21(4):1289. 524 525 526 50. Fortea J, Pegueroles J, Alcolea D, Belbin O, Dols-Icardo O, Vaqué-Alcázar L, et al. APOE4 homozygozity represents a distinct genetic form of Alzheimer's disease. Nat Med. 2024;30:1284-527 91. 528

529 530 51. Jack CR, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, et al. Revised criteria for diagnosis and 531 staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheimer's Dement. 2024;1-532 27. 533 534 52. Lehmann M, Ghosh PM, Madison C, Karydas A, Coppola G, O'Neil JP, et al. Greater medial temporal 535 hypometabolism and lower cortical amyloid burden in ApoE4-positive AD patients. J Neurol 536 Neurosurg Psychiatry. 2014;85(3):266-73. 537 Raulin AC, Doss S V., Trottier ZA, Ikezu TC, Bu G, Liu CC. ApoE in Alzheimer's disease: 538 53. 539 pathophysiology and therapeutic strategies. Mol Neurodegeneration. 2022;17(72). 540 541 54. Chen HK, Ji ZS, Dodson SE, Miranda RD, Rosenblum CI, Reynolds IJ, et al. Apolipoprotein E4 Domain 542 Interaction Mediates Detrimental Effects on Mitochondria and Is a Potential Therapeutic Target for Alzheimer Disease \*. Journal of Biological Chemistry. 2011;286(7):5215-21. 543 544 545 55. Flowers SA, Rebeck GW. APOE in the normal brain. Neurobiol Dis. 2020;136:104724. 546 547 56. Montagne A, Nation DA, Sagare AP, Barisano G, Sweeney MD, Chakhoyan A, et al. APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline. Nature. 2020;581(7806):71-6. 548

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

Matura S, Prvulovic D, Jurcoane A, Hartmann D, Miller J, Scheibe M, et al. Differential effects of the 57. ApoE4 genotype on brain structure and function. Neuroimage. 2014;89:81–91. 58. Operto G, Molinuevo JL, Cacciaglia R, Falcon C, Brugulat-Serrat A, Suárez-Calvet M, et al. Interactive effect of age and APOE-ε4 allele load on white matter myelin content in cognitively normal middleaged subjects. Neuroimage Clin. 2019;24:101983. Koutsodendris N, Blumenfeld J, Agrawal A, Traglia M, Grone B, Zilberter M, et al. Neuronal APOE4 59. removal protects against tau-mediated gliosis, neurodegeneration and myelin deficits. Nat Aging. 2023;3:275-96. 60. Liao F, Yoon H, Kim J. Apolipoprotein E metabolism and functions in brain and its role in Alzheimer's disease. Curr Opin Lipidol. 2017;28(1):67. Zheng JJ, Hong B V., Agus J, Guo F, Lebrilla CB, Jin L, et al. Alzheimer's Disease Patients, Especially 61. ApoE4 Carriers, Have Significantly Reduced High-density Lipoprotein Particle Size Revealed by Negative-stained Transmission Electron Microscopy. Alzheimer's Dement. 2022;18(e063375). **Acknowledgements** The authors would like to thank the ADNI team. Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01

AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (<a href="https://www.fnih.org">www.fnih.org</a>). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.

## **Funding**

This research was funded by the National Institute on Aging of the National Institutes of Health under award numbers R01AG070487 and R01AG062623. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

## **Author information**

# **Authors and Affiliations**

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

<sup>1</sup>Biodemography of Aging Research Unit, Social Science Research Institute, Duke University, Durham, NC, 27708-0408, USA. **Contributions** KA, SU, and ALR were involved in conceptualization, design and wrote the paper. OB, ALR, MD conducted data curation and formal analysis. KA, and AIY provided guidance on data analysis, interpreted the findings, and critically revised the manuscript. All authors have read and agreed to the published version of the manuscript. **Corresponding author** \$\$Correspondence to Konstantin G. Arbeev, Email address: ka29@duke.edu **Ethics declarations** The studies involving human subjects were approved by the Duke University Health System Institutional Review Board (Protocols Pro00105166 and Pro00105389). This publication includes only secondary analyses of existing data available from ADNI, and does not include identifiable human data. Written informed consent for ADNI participants was obtained by the ADNI in accordance with the local legislation and ADNI requirements. **Consent for Publication** Not applicable

Competing Interests

The authors declare no competing interests.

Additional information

Electronic Supplementary Material

Supplementary Material 1